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Abstract
Background: Although there have been studies of the genetic risk factors in the development of
stroke, there have been few investigations of role of genes in the cerebral response to ischemia.
The brain responds to ischemia in a series of reactions that ultimately influence the volume of a
stroke that, in general, correlates with disability. We hypothesize that polymorphisms in genes
encoding proteins involved in these reactions could act as modifiers of this response and impact
stroke volume. One of the pathways participating in the cerebral ischemic response involves
reactive oxygen species which can cause oxidative damage to nucleic acids. DNA repair
mechanisms are in place to protect against such damage and imply a role for DNA repair genes in
the response of the brain to ischemia and are potential candidate genes for further investigation.
Methods: We studied two common polymorphisms in the DNA repair gene, XRCC1, C26304T
and G28152A, in 134 well characterized patients with non lacunar ischemic strokes. We also
performed a case control association study with 113 control patients to assess whether these
variants represent risk factors in the development of ischemic stroke.
Results: Independent of etiology, the "T" allele of the C26304T polymorphism is significantly
associated with larger stroke volumes (T-test analysis, p < 0.044; multivariate regression analysis,
β = 0.23, p < 0.008). In the case control association study, we found that neither of these
polymorphisms represented a risk factor for the development of stroke.
Conclusion:  Our study suggests a major gene effect of the "T" allele of the C26304T
polymorphism modulating the cerebral response to ischemia in non lacunar ischemic stroke.
Background
Stroke is the leading cause of disability in North America
and with an annual estimate of 4 million survivors, there
are considerable emotional and financial costs in the care
of patients who have suffered cerebrovascular disease
[1,2]. As the population ages, the stroke rate more than
Published: 06 November 2006
BMC Medical Genetics 2006, 7:78 doi:10.1186/1471-2350-7-78
Received: 26 June 2006
Accepted: 06 November 2006
This article is available from: http://www.biomedcentral.com/1471-2350/7/78
© 2006 Dutra et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2006, 7:78 http://www.biomedcentral.com/1471-2350/7/78
Page 2 of 6
(page number not for citation purposes)
doubles for each successive decade after age 55 and it is
likely that morbidity will also continue to increase [3].
While there are recent research efforts exploring the role of
genetic factors that could contribute to the development
of stroke, there are few studies of the genetics of the cere-
bral response to ischemia. Studies of induced strokes in
transgenic animals indicate that manipulation of certain
genes can influence the resultant volume [4,5]. We
hypothesize that there is variability in the cerebral
response to ischemia which may be mediated by poly-
morphisms in genes encoding proteins that participate in
this response. Polymorphisms in these genes exerting a
major affect could enhance or diminish endogenous neu-
roprotective mechanisms and ultimately impact the vol-
ume of an ischemic stroke. This has clinical significance
because, in general, the volume of a stroke correlates with
the clinical severity and the resultant degree of disability
of the patient [6,7].
It is recognized that cerebral ischemic injury results in a
core of necrotic tissue surrounded by a penumbra of
potentially salvable tissue in which neurons are function-
ally inactive but can be rescued [8]. The development of
this ischemic penumbra is limited in time by a cascade of
biochemical events which are a consequence of the initial
ischemia followed by subsequent reperfusion. The reper-
fusion which occurs shortly after ischemia has been
shown to reduce infarct volume, but at a later period may
exacerbate ischemic injury [9]. It has been suggested that
reperfusion increases reactive oxygen species (ROS) pro-
duction which can have further deleterious consequences
[10-12]. Cell exposure to these ROS, which include nitric
oxide, superoxide ions and hydroxyl radicals, can result in
oxidative DNA damage. DNA repair enzymes function to
monitor and repair such damage [12-14].
A number of DNA repair genes have been described and
broadly can be divided into base excision repair (BER),
nucleotide excision repair (NER), and mismatch repair
(MMR). The BER pathway involves a coordinated action
of many core genes [15]. The X-ray repair cross-comple-
menting group 1 (XRCC1) gene-product plays a central
role in the DNA BER pathway by interacting with DNA
ligase III, DNA polymerase beta and poly (ADP-ribose)
polymerase [16]. The XRCC1 protein rejoins DNA strand
breaks and repairs gaps left during BER [17]. XRCC1 gene
expression levels are high in the brain and there is evi-
dence of involvement of this gene in cerebral tissue injury
[18].
We hypothesize that biologically significant polymor-
phisms in the XRCC1 gene could result in variability in
DNA repair capacity and modify the response of the brain
to cerebral ischemia ultimately influencing infarct vol-
ume. We selected polymorphisms in this gene for study
based upon conservation of the gene sequence through
evolution, frequency, and those occurring in exons result-
ing in amino acid changes of potential functional signifi-
cance [19]. Two common polymorphisms, the C26304T
(exon 6, Arg194Trp) and G28152A (exon 10, Arg399Gln)
in the XRCC1 gene were studied both as risk factors for the
development of stroke and as modifiers of the response of
the brain to ischemia.
Methods
Subjects
We characterized the clinical and demographic data on
134 patients admitted with non-lacunar ischemic infarcts
to the stroke unit at John F. Kennedy Medical Center, Edi-
son, New Jersey. In addition, 113 healthy age, sex and eth-
nically matched controls were recruited from local
physician offices. Strokes were categorized according to
the Trial of ORG 10172 in Acute Stroke Treatment
(TOAST) [20] and Oxfordshire criteria [21]. In the major-
ity of patients, (79%) diffusion MRI scans were available
for review, alternatively, cerebral CT scans (21%) were
used to measure stroke lesion volume. Patients given TPA
were excluded from the study. Infarction volume was esti-
mated by averaging the calculated values obtained from
direct measurements of the cerebral images by two exam-
iners by previously described methods [22]. All study pro-
tocols and methods were approved by the local
Institutional Review Board (IRB) at JFK Hospital.
Samples for variation screening
The samples screened for variation were the first 92 sam-
ples from the "DNA Polymorphism Discovery Resource"
at the Coriell Institute for Medical Research (Group I).
This resource was developed by the NIH in order to have
a common set of samples available to investigators screen-
ing for common variants existing in the general popula-
tion of the United States [25]. The samples are from U. S.
residents selected to represent the major ethnic groupings
of the population, although the ethnic origin of specific
individuals is unknown. The individuals in this sample set
are from population groups as follows: European-Ameri-
can 23; African-American 23; Mexican-American 11;
Native-American 11; Asian-American 23. As all samples
came from commercially available cell lines from healthy
anonymous donors, the protocol was considered exempt
by the Lawrence Livermore National Laboratory Review
Board under 10CRF745.101 (b).
Identification of XRCC1 variants
The resequencing strategy and data analysis methods
employed to identify variants is described elsewhere in
detail [23,24]. Briefly, this involved the sequencing of the
same genomic region in the 92 individuals in order to
identify DNA sequence variation. PCR products contain-BMC Medical Genetics 2006, 7:78 http://www.biomedcentral.com/1471-2350/7/78
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ing the individual exons of XRCC1, plus adjacent intronic
and non-coding regions were generated using oligonucle-
otide primers specific to XRCC1. It should be noted that
complete intronic and untranslated regions were not
sequenced in this study.
Variants genotyped
Two common amino acid substitution variants in XRCC1
were genotyped in this study. The Arg to Trp substitution
at residue 194 and nucleotide 685 (C/T) of cDNA refer-
ence sequence NM006297 is located at nucleotide
48749414 of the UCSC Genome Browser Golden Path
assembly of May 2004 and is SNP ID rs1799872 of
dbSNP. The Arg to Gln substitution at residue 399 is
nucleotide 1301 (G/A) located at nucleotide 48747566 of
the May 2004 assembly of Golden path and SNP ID
rs25487 in dbSNP.
Genotyping
Genomic DNA was isolated from blood samples (Pure-
gene Systems, Gentra). Standard PCR protocols, followed
by restriction enzyme digestions were used to genotype
the XRCC1 polymorphisms, as previously described [26].
Briefly, the primer pairs used were: C26304T, F 5'AGCTG-
TACCTGTCACTCCCC 3'and R 5' CCCTACTCACTCAG-
GACCCA 3'; G28152A, F GCCCCTCAGATCACACCTAA
5' and R 5'ATTGCCCAGCACAGGATAAG 3'. The PCR con-
ditions were modified from those published and con-
sisted of an initial melting temperature of 94°C for 4
minutes followed by 30 cycles of melting (94°C, 30 s),
annealing (64°C, 45 s) and extension (72°C, 45 s). A final
extension step (72°C, 7 min) terminates the reaction (Per-
kin-Elmer 9700). Ten ul of the PCR products were sub-
jected to restriction enzyme digestion for 15 hours
according to standard conditions for each enzyme pro-
vided by the supplier (New England Biolabs, MA). The
C26304T polymorphism was analyzed after digestion
with Pvu II and the G28152A variant with Msp I. Ten µl of
the digested products were resolved by gel electrophoresis
(6% polyacrylamide gel). The genotypes obtained by this
method were confirmed by direct sequencing. The allele
frequency was obtained by direct gene counting.
Statistical analysis
Observed numbers of each genotype was compared with
those expected under Hardy-Weinberg equilibrium
(HWE) by using the x2 test.
To investigate genetic susceptibility to stroke, we used the
2 × 3 contingency table for the x2 test or Fisher exact test to
determine whether genotype distributions were different
between cases and controls. In addition, we also tested for
any significant difference of allele frequencies between
cases and controls in a 2 × 2 table. To study the correlation
between these two polymorphisms and stroke volume,
ANOVA was used to test for differences between geno-
types and mean stroke volume. Multivariate regression
was carried out to study other covariates that may be
related to stroke volume. We evaluated the strength of
linkage disequilibrium (LD) between the two polymor-
phisms by Haploview [27]. The PHASE program was
employed to infer haplotypes and test for the association
between phenotypes and haplotypes/diplotypes [28].
Results
Among the patients, applying the TOAST classification,
the etiology of the non-lacunar ischemic strokes included
61 large artery atherothrombosis, 40 cardioembolic and
33 with other known or unknown causes (Table 1). The
infarct volume averaged 75 cm3 and ranged between 0.2
cm3 to 482 cm3.
The uncommon "T" allele frequency of the C26304T pol-
ymorphism was present in 8.0% of cases and 7.8% of the
controls (data not shown). The less common "A" allele
frequency of the G28152A polymorphism was found in
36.2% cases and 31.9% of the controls. The genotypes of
the two polymorphisms did not deviate from Hardy-
Weinberg equilibrium in either cases or controls. The D'
of two polymorphisms was 0.7, suggesting they are in LD.
Our analysis showed no differences in the frequencies or
genotypes of either of the two polymorphisms between
the stroke and control patients (p > 0.5).
There was only one subject with the TT genotype of the
C26304T variant and so we combined the CT and TT as
one group in the following analyses (Table 2). If only the
CT genotype was analyzed, the results were almost identi-
Table 1: Demographic and clinical characteristics of the patients
Female n (% female) 73 (54.5)
Mean age, years (SD a) 70.8 (12.9)
Ethnicity n (%)
Caucasians 93 (69.9%)
African Americans 12 (9.0%)
Others b 29 (21.6%)
Clinical characteristics c
Hypertension 100 (74.6%)
Diabetes 54 (39.1%)
Atrial Fibrillation 36 (27.3%)
TOAST Classification d
Cardioembolism 40 (29.9%)
Large-artery atherosclerosis 61 (45.5%)
Others e 33 (24.6%)
a S.D. – Standard deviation.
b Includes Hispanic, Asian, and other ethnic groups.
c Other clinical data recorded includes history of smoking, alcohol use, 
coronary artery disease, peripheral vascular disease, carotid stenosis, 
cholesterol profile, and homocysteine levels.
d TOAST – Trial of Org 10172 in Acute Stroke Treatment.
e Includes stroke of other determined etiology, and stroke of 
undetermined etiology.BMC Medical Genetics 2006, 7:78 http://www.biomedcentral.com/1471-2350/7/78
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cal. T- test analysis of the C26304T polymorphism
showed that the (CT + TT) group was associated with a sig-
nificantly larger ischemic lesion volume compared to the
CC genotype (p < 0.044). Analysis of the G28152A poly-
morphism showed significant differences of stroke vol-
ume among the three genotypes (p = 0.02). However,
including age, gender, DM, HTN, smoking and both pol-
ymorphisms in the multivariate regression model, we
found only the C26304T polymorphism (regression coef-
ficient, β = 0.23, p < 0.008) and gender (β = 0.22, p =
0.013 for males) were significantly associated with stroke
volume (Table 2). Haplotype and diplotype analyses did
not improve statistical significance (data not shown).
Subgroup analyses focusing on the large artery athero-
thrombosis patients showed that the CT variant of the
C26304T was still significantly associated with a larger
ischemic lesion volume compared to the CC genotype (p
= 0.045). In the multiple regression model for large vessel
thrombosis, only the CT genotype of the C26304T poly-
morphism (β = 0.43, p < 0.001) and gender (β = 0.31, p =
0.014 for males) were significant in this subgroup (Table
2).
Discussion
The frequencies of both the C26304T and the G28152A
polymorphisms in the population we studied are compa-
rable to published data [19,29,30]. There is no significant
difference in the frequencies of either of these polymor-
phisms between the control and stroke patients suggest-
ing that they do not represent a major genetic risk factor
for the development of stroke.
Our data show a trend towards larger volume strokes in
men. There has been little study of any potential relation-
ship between gender and acute ischemic stroke volume in
humans. Although our results are of interest, further study
with a larger sample size of patients with non-lacunar
strokes are needed to confirm if any gender differences in
stroke volume exist.
Our results indicate that the C26304T polymorphism is
associated with a significant difference in stroke volume.
The "T" allele is associated with higher ischemic stroke
volume independent of the etiology of the stroke. There is
no significant additive effect of the G28152A polymor-
phism genotypes or any clinical feature.
Even though the two SNPs are in linkage disequilibrium,
there is no association of stroke volume with the
G28152A polymorphism either independently or in hap-
lotype analysis. This suggests that there may be a func-
tional consequence of this specific polymorphism rather
than the effect of another tightly linked gene.
Although there are many reports studying the association
of both of these XRCC1 SNP in cancer, there have been
relatively few studies of their functional significance [26].
The C26304T polymorphism is located within the gene
region encoding that domain of the protein which inter-
acts with poly (ADP-ribose) polymerase that is required
for DNA repair [28,29].
Oxidative DNA damage can be reversed by DNA repair
mechanisms, usually within the first 30 min of reper-
fusion [30]. In cerebral ischemia, a temporal sequence of
oxidative stress-induced DNA damage starts with the
beginning of reperfusion-oxidative DNA base modifica-
tions, followed by the formation of direct DNA breaks,
and finally DNA fragmentation and cell death [30]. Stud-
ies of transient cerebral ischemia in animal models sug-
gest that an early decrease of XRCC1 protein levels and
failure of the DNA repair mechanisms could contribute to
DNA fragmentation [11,31-33]. A biologically plausible
hypothesis is that "T" allele of the C26304T polymor-
Table 2: Genotype and stroke volume data
SNP Genotype N Mean stroke Volume(cm3) ± SD βa P-valuea
All patients
C26304T CC 114 62.4 ± 74.5
CT + TTb 20 130.6 ± 138.6 0.233 0.008
TOAST-LAAc
C26304T CC 54 61.6 ± 80.0
CT 7 227.6 ± 174.3 0.434 0.001
TOAST-Non-LAA
C26304T CC 60 63.1 ± 68.8
CT + TTb 13 78.3 ± 82.4 0.074 0.564
a After adjusting for age, gender, DM, HTN, and smoking in the multivariate regression model
b TT genotype N = 1
c Toast Classification-Large Artery AtherosclerosisBMC Medical Genetics 2006, 7:78 http://www.biomedcentral.com/1471-2350/7/78
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phism reduces the fidelity of BER and thereby results in
more ROS species. This could subsequently contribute to
further oxidative DNA damage and perpetuate the cycle of
cerebral cellular and tissue damage.
This is one of the few reports studying the potential
genetic contribution in the cerebral response to ischemia
in humans. Although the study is limited by a relatively
small sample size, it is the first to demonstrate a potential
major gene effect of a polymorphism in any DNA repair
gene upon ischemic stroke volume. Further investigations
of the XRCC1 gene as a modifier of the cerebral response
in ischemic stroke in a larger sample size are needed to
confirm and expand on these results.
Genes encoding proteins that are participants in the cas-
cade of events that follow ischemia are candidates for fur-
ther study. In broad terms, the results of such studies may
have implications for future targeting efforts for the devel-
opment of more effective neuroprotective therapies.
Conclusion
Our study suggests that independent of stroke etiology,
there a major effect of the "T" allele of the C26304T poly-
morphism of the XRCC1 gene in the response of the brain
to non lacunar ischemic stroke.
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